CTLA4 and rheumatoid arthritis: Since cytotoxic T-lymphocyte-associated protein 4 (CTLA4) competes with CD28 for binding to CD80/86, biological therapies based on CTLA4 are approved for rheumatoid arthritis and kidney transplantation.